Department of Family Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea.
Department of Information & Statistics, Chungbuk National University, Cheongju, Republic of Korea.
Nutr Metab Cardiovasc Dis. 2020 Sep 24;30(10):1714-1722. doi: 10.1016/j.numecd.2020.05.010. Epub 2020 May 28.
Several studies have reported the preventive effect of metformin on cancer development. This study aimed to investigate the relationship between use of metformin and risk of cancer in Koreans.
This study was designed retrospectively using the National Health Insurance Service-National Health Screening Cohort conducted between 2002 and 2015. 40 to 69-year-old subjects who received a health screening examination from 2002 to 2003 were enrolled. Hazard ratios (HRs) and 95% confidence intervals (CIs) for cancer were estimated in a multivariate Cox proportional regression analysis. A total of 323,430 subjects was enrolled (301,905 individuals without diabetes [No DM], 8643 diabetic patients with metformin treatment [metformin users], and 12,882 diabetic patients without metformin treatment [metformin non-users]). The median follow-up period was 12.7 years. Cumulative incidence of overall cancer was 7.9% (7.7, 10.3, and 11.1% in No DM, metformin users and non-users, respectively). Compared to metformin non-users, the fully adjusted HRs (95% CIs) of metformin users and No DM for overall cancer incidence were 0.73 (0.66-0.81) and 0.75 (0.64-0.88), respectively, in men and 0.83 (0.78-0.89) and 0.81 (0.72-0.92) in women.
Diabetic patients receiving metformin treatment, and individuals without diabetes were at lower risk for cancer incidence than diabetic patients without metformin treatment.
多项研究报道了二甲双胍对癌症发展的预防作用。本研究旨在探讨韩国人群中使用二甲双胍与癌症风险的关系。
本研究使用 2002 年至 2015 年进行的国家健康保险服务-国家健康筛查队列进行回顾性设计。纳入了 2002 年至 2003 年接受健康筛查检查的 40 至 69 岁的受试者。使用多变量 Cox 比例风险回归分析估计癌症的风险比（HR）和 95%置信区间（CI）。共纳入 323430 名受试者（301905 名无糖尿病患者[无 DM]、8643 名接受二甲双胍治疗的糖尿病患者[二甲双胍使用者]和 12882 名未接受二甲双胍治疗的糖尿病患者[二甲双胍非使用者]）。中位随访时间为 12.7 年。总体癌症的累积发生率为 7.9%（无 DM、二甲双胍使用者和非使用者分别为 7.7%、10.3%和 11.1%）。与二甲双胍非使用者相比，男性中二甲双胍使用者和无 DM 的总体癌症发生率的完全调整 HR（95%CI）分别为 0.73（0.66-0.81）和 0.75（0.64-0.88），女性中分别为 0.83（0.78-0.89）和 0.81（0.72-0.92）。
接受二甲双胍治疗的糖尿病患者和无糖尿病的个体发生癌症的风险低于未接受二甲双胍治疗的糖尿病患者。
